Hunter Syndrome (Mucopolysaccharidosis Type II [MPS II]) research hub

A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants with Hunter Syndrome

This study is testing a new medicine called DNL310 for children with Hunter Syndrome. It's looking at how safe the medicine is, how the body handles it, and if it helps reduce certain substances linked to the condition.